Publicaciones (26) Publicaciones de MARTA LLARENA FERNÁNDEZ

2024

  1. De-imFAR phase II project: a study protocol for a cluster randomised implementation trial to evaluate the effectiveness of de-implementation strategies to reduce low-value statin prescribing in the primary prevention of cardiovascular disease

    BMJ Open, Vol. 14, Núm. 4

2023

  1. Validity and reliability of the transculturally adapted Spanish version of the Implementation Leadership Scale (ILS)

    Implementation Science Communications, Vol. 4, Núm. 1

2022

  1. Applying the behavior change wheel to design de-implementation strategies to reduce low-value statin prescription in primary prevention of cardiovascular disease in primary care

    Frontiers in Medicine, Vol. 9

2019

  1. Neurofisiología

    Daño cerebral (Editorial El Manual Moderno), pp. 39-91

2018

  1. Dislipemias genéticas

    Protocolos de diagnóstico y tratamiento de los errores congénitos del metabolismo (Ergon), pp. 135-154

2017

  1. Influence of phenylketonuria's diet on dimethylated arginines and methylation cycle

    Medicine (United States), Vol. 96, Núm. 27

  2. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: Patient perspectives

    Patient Preference and Adherence, Vol. 11, pp. 1489-1496

2016

  1. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 567-582

  2. Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

    Orphanet Journal of Rare Diseases, Vol. 11, Núm. 1

  3. Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 409-418

  4. Molecular epidemiology, genotype-phenotype correlation and BH 4 responsiveness in Spanish patients with phenylketonuria

    Journal of Human Genetics, Vol. 61, Núm. 8, pp. 731-744

  5. Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 555-566

2015

  1. 6R-tetrahydrobiopterin treated PKU patients below 4years of age: Physical outcomes, nutrition and genotype

    Molecular Genetics and Metabolism, Vol. 115, Núm. 1, pp. 10-16

  2. Corrigendum to "Tetrahydrobiopterin therapy vs phenylalanine-restricted diet: Impact on growth in PKU" [Mol. Genet. Metab. 109 (2013) 331-338]

    Molecular Genetics and Metabolism

  3. Dimethylarginines as biomarkers for the kidney transplant management in methylmalonic aciduria

    Nephrology, Vol. 20, Núm. 8, pp. 576-579

  4. Metabolomics in non-arteritic anterior ischemic optic neuropathy patients by liquid chromatography–quadrupole time-of-flight mass spectrometry

    Metabolomics, Vol. 11, Núm. 2, pp. 468-476

  5. Phenylketonuria's impact on physical growth in a Spanish cohort

    Phenylalanine: Dietary Sources, Functions and Health Effects (Nova Science Publishers, Inc.), pp. 27-48

  6. Quantification of arginine and its methylated derivatives in healthy children by liquid chromatography-tandem mass spectrometry

    Journal of Chromatographic Science, Vol. 53, Núm. 5, pp. 787-792

  7. Sanfilippo syndrome: Overall review

    Pediatrics International, Vol. 57, Núm. 3, pp. 331-338

2014

  1. A new case of maternal phenylketonuria treated with sapropterin dihydrochloride (6R-BH4)

    Gynecological Endocrinology, Vol. 30, Núm. 10, pp. 691-693